Drugs / Anti-CDH17 CAR-T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06820424 | Mar 2025 → Jan 2028 expected | — | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06501183 | Jul 2024 → May 2025 overdue | — | Shanghai Pudong Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CDH17 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06501183 ↗ |
| Modality | Cell therapy | “Anti-CDH17 CAR-T cell injection” NCT06501183 ↗ |
| Route | Intravenous | “intravenous infusion of anti-CDH17 CAR-T Cells” NCT06820424 ↗ |
| Target | CDH17 | “Anti-CDH17 CAR-T cell injection” NCT06501183 ↗ |